收藏产品 产品信息
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The CHO/Human CD79B Stable Cell Line was engineered to express the receptor full length human CD79B (Gene ID: 974), used to mimic cancer target cells. Surface expression of human CD79B was confirmed by flow cytometry.
应用说明（Application）
• Useful for cell-based CD79B binding assay.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL)
培养基（Complete Growth Medium）
F-12K + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
产品数据图
Receptor Assay
Expression analysis of human CD79B on CHO/Human CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79B Stable Cell Line or negative control cell using APC-labeled anti-human CD79B antibody.
Protocol
产品评论 发表评论
背景
B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
靶点信息 
数据表和文档 
联系我们 
项目合作